盐酸索他洛尔的合成

苯胺与甲磺酰氯反应得到N-苯基甲磺酰胺,然后与氯乙酰氯进行酰化反应得到N-[4-(2-氯乙酰基)苯基]甲磺酰胺,随后经异丙胺化得到N-[4-(2-异丙胺基乙酰基)苯基]甲磺酰胺盐酸盐,最后经还原反应后成盐制得盐酸索他洛尔,总收率约64％(以苯胺计).     

药品行政保护品种介绍:心血管药物(一)(待续)

琥珀酸美托洛尔(metoprololsuccinate)缓释片　通用名:琥珀酸美托洛尔。商品名:ToprolXL。化学名:(±)11(异丙氨基)3对(2甲氧乙基)苯氧基2丙醇琥珀酸(2∶1)盐。结构式见图1。X图1　琥珀酸美托洛尔结构式Fig1　Structrueofmetoprololsuccinate　　申请日:2001年11月1日。申请人     

美托洛尔片剂含量的高效液相色谱法测定

美托洛尔是一种选择性的β1受体阻断剂，化学名为1-[4-(2-甲基乙基)苯氧基]-3-异丙氨基丙醇-(2)酒石酸盐。临床用于治疗轻、中度高血压、稳定性心绞痛及心律失常。文献[1～3]报道了血浆中美托洛尔浓度的测定，流动相多用乙腈，常规分析有比色法、紫外分光光度法和     

琥珀酸美托洛尔的合成工艺改进

目的 优化琥珀酸美托洛尔的合成路线.方法 以4-(2-甲氧基乙基)苯酚和环氧氯丙烷为原料在相转移催化剂四丁基溴化铵催化下,先得到1-(2,3-环氧丙氧基)-4-(2-甲氧基乙基)-苯;再与异丙胺在催化剂AlCl3的作用下反应,得到美托洛尔;最后将美托洛尔与琥珀酸的饱和乙醇溶液反应即得琥珀酸美托洛尔.结果 目标化合物琥珀酸美托洛尔的结构经核磁共振氢谱(1 H-NMR)和电喷雾质谱法(ESI-MS)确证,高效液相色谱法测定纯度为99.01%,总收率为51.8%.结论 本实验工艺简单,反应时间短,收率较高,产品纯度好,而且在较大程度上降低了环境污染,绿色环保.     

β-受体阻滞剂盐酸艾司洛尔的合成

艾司洛尔 (esmolol,1 )是一种具有心脏选择性的超短效 β-受体阻滞剂 ,其作用特点是起效快、作用时间短和选择性阻滞β1-受体。在文献报道的合成方法中 ,有以 4- [(2 ,3-二羟基 )丙氧基 ]苯丙酸甲酯为原料 ,先与亚硫酰氯反应生成环状亚硫酸酯 ,再与异丙胺反应得到 1 [1] ;也有将对羟基苯丙酸先制成甲酯 ,用环氧氯丙烷醚化 ,再经异丙胺胺化得 1 [2 ,3] 。本文以对羟基苯甲醛 (2 )为起始原料 ,按文献 [4 ]醚化制得 4- (2 ,3-环氧丙氧基 )苯甲醛 (3) ,经异丙胺胺解后 ,在吡啶存在下直接与丙二酸缩合得到 5,酯化后再经钯 /炭常压催化氢化制得 1 …     

α-溴-(2-羟基-4-甲磺酰胺基-5-苯氧基)苯乙酮的合成

以3-甲磺酰胺基-4-苯氧基苯甲醚为原料，在AlCl3作用下，经付-克乙酰化同时脱甲基化反应得到（2-羟基-4-甲磺酰胺基-5-苯氧基）苯乙酮，再经溴化得到标题化合物，总收率70%。     

帕尼培南关键中间体的合成

目的: 改进帕尼培南关键中间体(S)-1-[N-(对硝基苄氧羰基)-1-亚胺基乙基]-3-巯基吡咯烷的合成工艺。方法:以对硝基苄醇为起始原料,经酰化、缩合、与3-R-羟基吡咯烷发生N-烃基化反应,再经磺酰化、缩合、水解反应得到目标化合物。结果与结论:以对硝基苄醇为起始原料经6步反应得到目标化合物,结构经IR、1H-NMR、MS谱图数据确证,比旋光度值与文献报道一致。改进后的工艺总收率为37.2%,各步反应操作简便,条件温和,更适合工业化生产。     

倍他索洛尔(Betaxolol)

异名 Kerlon,Kerlone 化学名消旋1-[4-[2-(环丙基甲氧基)乙基]苯氧基]-3-异丙胺基-2-丙醇盐酸盐药效分类抗高血压药开发单位 Synthelabo 上市厂商 (法)Robert公司和Carriere公司首次报道 Br J Pharmacol 1979,66:445 药理本品为心脏选择性β-肾上腺素能受体阻滞剂。其β阻滞作用为心得安的4倍,无内源性拟交感作用,有很弱的膜稳定作用。口服生物利用度高,消除半衰期长。临床试验结果表明是一有效的抗高血压新药。     

3-甲胺基哌啶合成工艺

在(±)-1-环丙基-6-氟-8-甲氧基-7-[3-(甲胺基)哌啶-1-基]-4-氧代-1,4-二氢喹啉-3-羧酸二水合物(即巴洛沙星)的合成过程中,关键中间体3-甲胺基哌啶的收率问题决定着合成巴洛沙星的成本。关键中间体3-甲胺基哌啶可以以3-溴吡啶为原料,用甲胺取代,再经催化氢化等反应合成得到,收率约为48%。     

抗阿尔茨海默病药物2-羟基-5-[2-(4-(三氟甲基苯基)乙基氨基)]苯甲酸的合成

目的:合成2-羟基-5-[2-(4-(三氟甲基苯基)乙基氨基)]苯甲酸。方法:以对三氟甲基氯苯和5-氨基水杨酸为起始原料通过5步反应合成了细胞坏死抑制剂2-羟基-5-[2-(4-(三氟甲基苯基)乙基氨基)]苯甲酸。结果与结论:目标产物结构经1H-NMR,13C-NMR和ESI-MS确证,总产率为37.7%。该合成路线具有原料价廉易得、反应条件温和、收率高、操作简便的特点,适合于工业化生产。     

组胺H3受体拮抗剂／反向激动剂pitolisant的合成

目的对组胺H3受体拮抗剂／反向激动剂pitolisant进行合成工艺研究。方法以对氯氯苄、丙二酸二乙酯为起始原料，经过缩合、水解、脱羧、还原、酯化、取代反应制得pitolisant。结果与结论经过6步反应合成目标化合物pitolisant，其结构经1H—NMR及MS确证。对其中多步反应条件进行了工艺考察及优化，总收率为31．4％（以对氯氯苄计）。     

盐酸阿罗洛尔的合成

噻吩经5步反应获得5-乙酰噻吩-2-羧酸,然后与氯化亚砜、氨水反应得到5-乙酰噻吩-2-甲酰胺,再与溴素及二硫代氨基甲酸铵反应生成5-(2-巯基-4-噻唑基)-2-噻吩甲酰胺,后者与环氧氯丙烷缩合后经叔丁胺开环,最后与盐酸成盐得到盐酸阿罗洛尔,总收率约6%.     

达比加群酯的合成工艺改进

目的 改进达比加群酯的合成工艺,提高反应收率并简化操作。方法 以4-甲胺基-3-硝基苯甲酸为原料,与3-（吡啶-2-基氨基）丙酸乙酯缩合后,经催化氢化、酰胺化后闭环、成脒、与氯甲酸正己酯反应得到达比加群酯。结果与结论 目标化合物的结构经核磁共振氢谱、质谱确证。改进后的合成方法与原工艺相比,环境友好,收率提高了16.4%,总收率为33.75%(以4-甲胺基-3-硝基苯甲酸计)。     

抗乙肝病毒药物恩替卡韦的合成

目的合成抗乙肝病毒（HBV）药物恩替卡韦。方法以（1S-反式）-2-[（苯甲氧基）甲基]-3-环戊烯-1-醇为起始原料,经环氧化、保护羟基、定向加成、保护氨基、氧化、亚甲基化和两步脱保护基合成目标化合物。结果实验总收率为8.9%,其结构经红外、质谱、氢谱和碳谱测试确证。结论该工艺与文献相比操作简便,易于工业化大生产,收率高。     

(Aminomethyl)aryloxy]acetic acid esters. A new class of high-ceiling diuretics. 1. Effects of nitrogen and aromatic nuclear substitution

A series of Mannich bases and aminomethyl derivatives of ethyl [2,3-dichloro-4-(4-hydroxybenzoyl)phenoxy]acetate were synthesized and tested for saluretic and diuretic activities. The effects of nitrogen and aromatic nuclear substitution, reorientation of the aminomethyl group relative to that of the phenolic hydroxyl group, and replacement of either the phenolic hydroxyl or the aminomethyl group by other functional groups are described. Ethyl [2,3-dichloro-4-[3-(aminomethyl)-4-hydroxybenzoyl]phenoxy]acetate (27) was found to be a very potent, high-ceiling diuretic.     

Facile radiosynthesis of fluorine-18 labeled beta-blockers. Synthesis, radiolabeling, and ex vivo biodistribution of [18F]-(2S and 2R)-1-(1-fluoropropan-2-ylamino)-3-(m-tolyloxy)propan-2-ol

An efficient and general method has been developed for fluorine-18 labeling of beta-blockers that possess the propanolamine moiety. A new synthetically versatile intermediate, 3-(1-(benzyloxy)propan-2-yl)-2-oxooxazolidin-5-yl)methyl 4-methylbenzenesulfonate (13), was prepared and can be conjugated to any phenoxy core. To demonstrate the synthetic methodology, fluorinated derivatives of toliprolol were prepared, namely, [(18)F]-(2S and 2R)-1-(1-fluoropropan-2-ylamino)-3-(m-tolyloxy)propan-2-ol ((2S and 2R)-[(18)F]1). The radiosyntheses were accomplished in <1 h, with 20-24% (uncorrected for decay, n = 7) radiochemical yields, >96% radiochemical and >99% enantiomeric purities, with specific activities of 0.9-1.1 Ci/micromol (EOS). Ex vivo biodistribution studies with the radiotracers demonstrated excessively rapid washout that may limit their use for cerebral PET imaging.     

Binding and functional affinity of some newly synthesized phenethylamine and phenoxypropanolamine derivatives for their agonistic activity at recombinant human beta3-adrenoceptor

Beta(3)-adrenoceptor is the predominant beta-adrenoceptor in adipocytes and has drawn much attention during the investigation for anti-obesity and antidiabetes therapeutics. Thirteen new compounds have been evaluated for their potencies and efficacies as beta(3)-adrenoceptor agonists on human beta(3)-adrenoceptor expressed in COS-7 and Chinese hamster ovary (CHO) cells using radioligand binding assay and cyclic AMP (cAMP) accumulation assay. Phenoxypropanolamine derivatives, SWR-0334NA (([E)-[4-[5-[(3-phenoxy-2-hydroxypropyl)amino]-2-pentene-3-yl] phenoxy]acetic acid sodium salt), SWR-0335SA ((E)-[4-[5-[(3-phenoxy-2-hydroxypropyl)amino]-2-pentene-3-yl] phenoxy] acetic acid ethanedioic acid), SWR-0342SA (S-(Z)-[4-[[1-[2-[(2-hydroxy-3-phenoxypropyl)]amino] ethyl]-1-propenyl]phenoxy] acetic acid ethanedioic acid), SWR-0348SA-SITA ((E)-[4-[5-[(3-phenoxy-2-hydroxypropyl)amino]-2-hexene-3-yl] phenoxy]acetic acid ethanedioic acid) and SWR-0361SA ((E)-N-methyl[4-[5-[(3-phenoxy-2-hydroxypropyl)amino]-2-pentene-3-yl]phenoxy]acetoamide ethanedioic acid) showed higher agonistic activity for the beta(3)-adrenoceptor. Among the compounds tested, SWR0334NA exhibited full agonist activity (%E(max) = 100.26) despite its lower binding affinity (pK(I) = 6.11). Compounds SWR-0338SA ((E)-[4-[5-[(2-phenyl-2-hydroxyethyl)amino]-2-pentene-3-yl] phenoxy]acetic acid ethanedioic acid), SWR-0339SA (S-(E)-[4-[5-[(3-phenoxy-2-hydroxypropyl)amino]-2-pentene-3-yl] phenoxy] acetic acid ethanedioic acid), SWR-0345HA ((E)-2-methyl-3-[4-[2-(2-phenyl-2-hydroxyethyl-amino)ethoxy] phenyl]-2-propenoic acid ethyl ester hydrochloride), SWR-0358SA ((E)-(2-methoxyethyl)-[4-[5-[(3-phenoxy-2-hydroxypropyl) amino]-2-pentene-3-yl]phenoxy]acetoamide ethanedioic acid) and SWR-0362SA ((E)-1-[[[4-[5-[(3-phenoxy-2-hydroxypropyl)amino]-2-pentene-3-yl]phenoxy]acetyl]carbonyl]piperidine ethanedioic acid) had moderate agonistic activity and were phenethylamine and phenoxypropanolamine derivatives. Compounds SWR-0065HA ([4-[2-[3-[[(3,4-dihydro-4-oxo-[1,2,4]-triazino(4,5-a)indol)-lyl]oxy]-2-hydroxypropylamino]ethoxy]phenyl]acetic acid methyl ester hydrochloride), SWR-0098NA ((E)-[4-[3-[(2-phenyl-2-hydroxyethyl)amino]-1-butenyl] phenoxy]acetic acid sodium salt) and SWR-0302HA ([4-[[4-[2-(3-chlorophenoxy-2-hydroxypropyl)amino]-E-2-butenyl]oxy]phenoxy]acetic acid hydrochloride) had very low binding affinity towards beta(3)-adrenoceptors and they did not induce cAMP accumulation. We concluded that compounds SWR-0334NA, SWR-0335SA, SWR-0342SA, SWR-0348SA-SITA and SWR-0361SA were potential agonists of human beta(3)-adrenoceptor. Further investigation on their selectivity towards beta(3)-adrenoceptor could be useful for the exploration of the physiological properties of the beta(3)-adrenoceptor.     

1-氯-2-甲基-4-乙酰氧基-2-丁烯的制备

异戊二烯与三氯异氰脲酸和水进行氯醇化反应,得1-氯-2-甲基-3-丁烯-2-醇和4-氯-3-甲基-2-丁烯醇,该混合物在对甲苯磺酸催化下与乙酐反应,得1-氯-2-甲基-4-乙酰氧基-2-丁烯,总收率约为61%,纯度93.5%。     

New 3-[4-(2,3-dihydro-14-benzodioxin-5-yl)piperazin-1-yl]-1-(5-substituted benzo[b]thiophen-3-yl)propanol derivatives with dual action at 5-HT(1A) serotonin receptors and serotonin transporter as a new class of antidepressants

Compounds derived from 2,3-dihydro-(1,4-benzodioxin-5-yl)piperazine and benzo[b]thiophene with different substituents in 5 position (H, F, NO2, NH2, CH3 and OH) have been synthesized in order to obtain new dual antidepressant drugs. The final compounds were evaluated for in vitro 5-HT(1A) receptor affinity and serotonin reuptake inhibition by radioligand assays. Compounds 1-(5-nitrobenzo[b]thiophen-3-yl)-3-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]propan-1-ol (4c) (Ki = 6.8 for 5-HT(1A) receptor and Ki = 14 for 5-HT transporter) and 1-(5-hydroxybenzo[b]thiophen-3-yl)-3-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl] propan-1-ol (4f) (Ki = 6.2 for 5-HT(1A) receptor and Ki = 18.2 for 5-HT transporter) showed the best results for both activities.     

SYNTHESIS OF THE RIGID ANALOGUES OF AN SSRI BENZENEPROPANAMINE

Several 1-(substituted phenoxy)-3-{[4-(4-trifluoromethyl) phenoxy] piperidin-1-yl} propan-2-ols (str.II) were prepared in a six-step reaction sequence starting from methylamine and ethyl acrylate and evaluated for antidepressant activity. The compounds were fully characterized by spectral and elemental analyses, and were tested for their effect on gross behavior, antireserpine and anorexigenic activity. No effect was observed on gross behavior and some of them showed fluoxetine like antireserpine and anorexigenic activity.